MedCity News

MedCity Pivot: How Aetna is Adopting Agentic AI

AI in Drug Development is Not a Data Problem — It’s An Evidence Problem

Drug development isn't limited by the amount of data we collect, but by our ability to preserve the context, meaning and relationships that transform data into evidence.

By Narasimha Kumar

Artificial Intelligence, Health Tech, Providers

A female healthcare worker pushing a giant stack of papers isolated on a white background showing burnout

How to Keep Clinicians Satisfied, the Ascension Way

Ascension is pushing AI beyond note-taking to tackle the billing, order entry and nursing handoff work still weighing on clinicians after a patient visit ends.

By Katie Adams

Compliance Alone Won’t Fix the Home Health Fraud Problem

With home health fraud growing more sophisticated through AI, post-pay audits are no longer enough. Payers must shift to proactive, tech-driven prevention to catch improper claims before paying them.

By Erin Rutzler, Cotiviti

Latest Video

Latest News

BioPharma, Pharma

Braveheart Bio’s $382M IPO for Heart Drug Leads a Big Week for Biotech IPOs

In addition to pricing the biggest biotech IPO of the week, Braveheart Bio’s underwriters exercised their option to purchase more shares, boosting the clinical-stage company’s total haul to nearly $440 million. Braveheart’s lead drug could be competitive with a blockbuster Bristol Myers Squibb medicine for a type of cardiomyopathy.

By Frank Vinluan

Consumer / Employer

MedCity FemFwd: Employer Strategies for Women’s Health

In this episode, we’re joined by Cheryl Larson, president and CEO of the Midwest Business Group on Health, for our first in-person recording at MedCity News’ recent Bullseye event.

By Marissa Plescia

Health Tech

Two Differing POVs Emerge About the Hinge-Cylinder Deal

Hinge Health’s acquisition of Cylinder expands it into GI care, but experts differ on whether employers will favor convenience or specialized solutions.

By Marissa Plescia

BioPharma, Pharma

Latigo Bio’s IPO Lands $346M for Pipeline of Non-Opioid Pain Drugs

Latigo Biotherapeutics will apply the IPO proceeds toward a pipeline that includes a next-generation non-opioid pain drug ready for pivotal testing. BlossomHill Therapeutics also debuted on the Nasdaq, raising cash for cancer drugs designed to address mutations not covered by currently available therapies.

By Frank Vinluan

MedCity Influencers

Why Kidney Care’s Biggest Investment Wave Hasn’t Moved Hospital Costs

The problem may not be the investment. It may be the target of the intervention.

By John Erbey

Where Will AI Deployment Benefit Payers the Most?

We are taking a look at how health insurers are using AI, defining success, and managing cybersecurity risks. Give us your opinions by completing our brief, anonymous survey.

By MedCity News

Opinion

My Wish For Better Care For Americans Living in Rural Areas

A letter to Medicaid Directors, State Leaders, and other invested collaborators who were awarded Rural Health Transformation (RHT) Grant funding.

By Lynda Rowe

BioPharma, Policy, Providers, Legal

The US Capitol Building in Washington DC, at an angle, over some trees. The beautiful dome stretches up into the blue sky with scattered clouds.

Bipartisan Lawmakers Are Fighting HHS’ 340B Rebate Push

A bipartisan group of six senators introduced a bill to reform the 340B drug program, locking in hospitals' use of contract pharmacies and adding new transparency and compliance rules. The legislation would also kill HHS' contested rebate pilot within a year and replace it with a national data clearinghouse to catch duplicate discounts.

By Katie Adams

BioPharma, Pharma

Recovery for Replimune: Accelerated Approval for Cancer Drug Twice Spurned by FDA

Replimune went from an FDA rejection to a resubmission, a positive advisory committee vote, and finally an accelerated regulatory approval for advanced melanoma — all in less than four months. The FDA nod for Replimune’s oncolytic viral therapy, Tudriqev, positions it as a more convenient alternative to an Iovance Biotherapeutics cell therapy that had been the only treatment in this setting.

By Frank Vinluan

Policy

Democratic Senators Urge Withdrawal of Interim Final Rule on Medicaid Work Requirements

Democratic senators are urging CMS to withdraw its Medicaid work requirements rule, arguing it will create administrative burdens and cause eligible beneficiaries to lose coverage.

By Marissa Plescia

MedCity Influencers

The Missing Piece of Preventive Dental Care Lies in the Bite

Historically, prevention has focused on protecting teeth from decay and gum disease. However, long-term oral health is also shaped by how the teeth, muscles, and jaw function together over time.

By Dr. Robert B. Kerstein

MedCity Influencers

illustration of man crossing surreal road, risk concept black and white risk

Healthcare Workplace Violence Prevention Needs Better Visibility Into Risk Signals

Gaps in prevention are not frequently due to a complete lack of information, but instead the fact that organizations don't have a clear way to see how the pieces fit together until after an incident has occurred.

By Brian Stromberg

Events, Health Tech

INVEST Digital Health Conference Returns with Focus on Consumers

Scheduled for October 29 at Pegasus Park in Dallas, the theme of the INVEST Digital Health conference will be consumers in healthcare from d2c diagnostics to GLP-1 drugs and wearables. Register today!

By Stephanie Baum

BioPharma, Pharma

Moderna Gets FDA Approval for mRNA Flu Vaccine, But CDC Input Still Uncertain

The FDA approved Moderna’s flu vaccine mFLUSIVA, a regulatory decision that comes six months after the agency refused to review the mRNA shot and then quickly reversed its position. But a recommendation from a Centers for Disease Control and Prevention advisory committee is key for payer coverage, and that committee has not met all year due to ongoing litigation.

By Frank Vinluan

Consumer / Employer

Report: What Employers Think About ICHRAs

A new survey found that many employers are considering ICHRAs, though concerns about awareness, affordability and the individual insurance market continue to slow adoption.

By Marissa Plescia

Health Services, Policy, Payers

Debunked Episode 29: CMS GLP-1 Drug Pilot Program, RPM Strategy Raise Questions

At MedCity News’ inaugural Bullseye conference in Chicago, Debunked Podcast co-hosts Arundhati Parmar and Samir Batra discussed recent CMS actions and Mayo Clinic’s former research director, who has filed a complaint against the medical center over how it’s deploying AI.

By Stephanie Baum